NCT05430386 - Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC | Biotech Hunter

Enrollment

174

Participants

Timeline

Start Date

January 5, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

HS-10241

"Dose escalation: HS-10241 and Almonertinib will be administered in combination. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.~Dose expansion: HS-10241 and Almonertinib will be administered in the dose identified in Part 1 to further investigate the safety, tolerability, pharmacokinetics, and efficacy of this combination therapy."

Trial Locations (1)

200032

RECRUITING

Shanghai Chest Hospital, Shanghai